Company release
13.50 Finnish time / 12.50 Swedish time
Resolutions of the Constitutive Meeting of the Board of Directors of
The meeting elected the following persons to the
For further information, please contact:
General Counsel
peter.hanninen@nanoform.com
+358 50 353 0408
For investor relations queries, please contact:
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in
https://news.cision.com/nanoform/r/resolutions-of-the-constitutive-meeting-of-the-board-of-directors-of-nanoform-finland-plc,c3962274
https://mb.cision.com/Main/18905/3962274/2735061.pdf
(c) 2024 Cision. All rights reserved., source